CRU Hungary Kft.
- Address
- Petofi Ut 26a, 3860 Encs, Hungary
CRU Hungary Kft.
CRU Hungary Kft. is a clinical research organization specializing in cardiometabolic disorders and chronic inflammatory diseases. The center demonstrates particular expertise in evaluating novel therapeutic agents for complex cardiovascular and metabolic conditions, with a strong focus on lipid metabolism disorders and atherosclerotic cardiovascular disease.
- Cardiovascular disease prevention and treatment, including atherosclerotic heart disease and evaluation of major adverse cardiac events (MACE)
- Lipid metabolism disorders, specifically severe hypertriglyceridemia and hypertriglyceridemia with atherosclerotic complications
- Chronic obstructive pulmonary disease (COPD) with emphasis on moderate to severe cases with frequent exacerbations
- Rheumatoid arthritis management, including studies of JAK inhibitors and biologic therapies in methotrexate-inadequate responders
The facility conducts comprehensive Phase 3 clinical trials evaluating both traditional and innovative treatment modalities, including cholesterol ester transfer protein (CETP) inhibitors, antisense oligonucleotides for lipid management, biologic therapies for respiratory and autoimmune conditions, and JAK inhibitors. Their research portfolio reflects expertise in assessing both efficacy endpoints such as cardiovascular risk reduction and structural disease progression, as well as long-term safety profiles of novel therapeutic agents.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Eli Lilly & Co.3active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB10trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CRU Hungary Kft.
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. | Amgen Inc. | Phase II | Not Recruiting | Mar 2023 | Oct 2025 |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Maridebart Cafraglutide | 4 | Unknown | 2023-03-10 | 2025-10-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.